Pleural MesotheliomaNCT07449624
From Presentation to Diagnosis: Patterns of Pleural Effusion
An observational study of Pleural Mesothelioma, run by Mansoura University Hospital at 1 site in Egypt.
Trial summary
Pleural effusion is a common clinical condition characterized by the accumulation of excess fluid within the pleural space due to disruption of normal pleural fluid dynamics. The etiology is diverse and includes systemic conditions such as congestive heart failure, liver cirrhosis, and renal disease, as well as… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pleural Mesothelioma
- What is being tested?
- Pleural effusion pathology
- How many people
- 300 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2020to 1 Jan 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients (>18 years) diagnosed with pleural effusion between January 2020 and December 2025.
Who may be able to join
- All patients with documented pleural effusion confirmed by chest imaging (X-ray, ultrasound, or CT).
- Patients with complete clinical, laboratory, and radiological records.
Who cannot join
- Patients with incomplete medical records.
- Pediatric patients (<18 years).
- Patients with post-surgical pleural collections unrelated to systemic or pathological causes.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: From Presentation to Diagnosis: Patterns and Etiologies of Pleural Effusion - A Retrospective Study at Mansoura University
Pleural effusion is a common clinical condition characterized by the accumulation of excess fluid within the pleural space due to disruption of normal pleural fluid dynamics. The etiology is diverse and includes systemic conditions such as congestive heart failure, liver cirrhosis, and renal disease, as well as localized pleural pathologies including infection, malignancy, and inflammatory disorders. Accurate classification of pleural effusion into transudative and exudative types, primarily using biochemical parameters such as Light's criteria, remains the cornerstone of diagnostic evaluation and guides subsequent clinical management.
Read the detailed description
Recent evidence emphasizes that differentiation based on biochemical and radiological characteristics significantly influences clinical decision-making. Exudative effusions usually reflect pleural inflammation or injury and often require further diagnostic procedures, such as cytological examination or thoracoscopy, to determine specific causes including malignancy or tuberculosis. In contrast, transudative effusions are typically associated with systemic disorders and are generally managed by treating the underlying condition.
Although Light's criteria continue to serve as the standard diagnostic tool, ongoing research seeks to refine diagnostic thresholds and explore adjunctive biochemical markers and imaging modalities to improve sensitivity and specificity in distinguishing effusion types and identifying underlying etiologies.
Several international studies have described the epidemiology and causes of pleural effusion across different populations; however, data from Egypt remain limited, particularly from tertiary care centers such as Mansoura University Hospitals. Understanding the patterns and etiologies of pleural effusion within a specific population-especially in regions with distinct epidemiological characteristics-is essential from both scientific and clinical perspectives.
Accurate categorization into transudative and exudative effusions using biochemical and imaging criteria allows clinicians to tailor the diagnostic approach appropriately. While transudative effusions often require conservative management targeting the primary systemic condition, exudative effusions frequently necessitate more invasive investigations, including pleural biopsy, thoracoscopy, or advanced imaging techniques to establish a definitive diagnosis.
Such stratification helps minimize unnecessary invasive procedures, reduce diagnostic delays, and optimize healthcare resource utilization-particularly in settings with limited access to advanced interventional diagnostics. Furthermore, local data regarding prevalence and clinical presentation provide valuable insights into regional disease burdens, such as higher rates of tuberculosis or malignancy, thereby supporting more effective healthcare planning and targeted management protocols.
Finally, adopting a comprehensive approach that integrates clinical assessment, radiological findings, and pleural fluid analysis aligns with contemporary evidence-based recommendations for pleural disease evaluation, ensuring that the study findings are applicable to both local and international clinical practice.
- Conditions
- Pleural Mesothelioma
- Being tested
- Pleural effusion pathology
- Keywords
- Pleural effusion, Thoracoscopy, Pleural biopsy
- Medical subject headings
- Mesothelioma, Malignant, Pleural Effusion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pleural effusion pathologyDiagnostic test
describe the demographic and clinical characteristics of patients presenting with pleural effusion.
To classify pleural effusions into transudates and exudates using Light's criteria.
To determine the most common etiologies of pleural effusion in Mansoura University.
To evaluate the relationship between clinical presentation, radiological findings,
| Study group | Role | What they receive |
|---|---|---|
| Pleural effusion | evaluate the patterns, clinical features, pleural fluid characteristics, and etiologies of Pleural effusion among patients treated at Mansoura University, providing a comprehensive overview of the disease in this region. Receives: Diagnostic Test: Pleural effusion pathology |
What is being measured
The primary outcome is the main question the study is designed to answer.
Distribution of underlying etiologies of pleural effusion among patients treated at Mansoura University Hospitals
Number of patients diagnosed with each underlying cause of pleural effusion (e.g., malignancy, tuberculosis, parapneumonic effusion, heart failure, liver cirrhosis, renal failure, and others) based on clinical evaluation, radiological findings, and pleural fluid analysis.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2026
- Study start1 Jan 2020
- Primary completion1 Dec 2025
- Study completion1 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pleural MesotheliomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mansoura University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Abd Elmoniem Mohamed, Mansoura University Hospital
- Investigators
- Mohamed AbdElmoniem, Principal investigator, Lecturer of chest medicine faculty of medicine Mansoura university
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07449624
- Sponsor's protocol ID
- R.26.02.3598
- Status last verified
- Mar 2026
- First submitted
- 26 Feb 2026
- Last updated
- 4 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- From Presentation to Diagnosis: Patterns and Etiologies of Pleural Effusion - A Retrospective Study at Mansoura University
- ClinicalTrials.gov ID
- NCT07449624
- Acronym / sponsor ID
- R.26.02.3598
- Conditions
- Pleural Mesothelioma
- Keywords
- Pleural effusion, Thoracoscopy, Pleural biopsy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 300 participants (actual)
- Lead sponsor
- Mansoura University HospitalUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 1 Dec 2025 (actual)
- Study completion
- 1 Jan 2026 (actual)
- First posted
- 4 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pleural effusion is a common clinical condition characterized by the accumulation of excess fluid within the pleural space due to disruption of normal pleural fluid dynamics. The etiology is diverse and includes systemic conditions such as congestive heart failure, liver cirrhosis, and renal disease, as well as localized pleural pathologies including infection, malignancy, and inflammatory disorders. Accurate classification of pleural effusion into transudative and exudative types, primarily using biochemical parameters such as Light's criteria, remains the cornerstone of diagnostic evaluation and guides subsequent clinical management.
Detailed description
Recent evidence emphasizes that differentiation based on biochemical and radiological characteristics significantly influences clinical decision-making. Exudative effusions usually reflect pleural inflammation or injury and often require further diagnostic procedures, such as cytological examination or thoracoscopy, to determine specific causes including malignancy or tuberculosis. In contrast, transudative effusions are typically associated with systemic disorders and are generally managed by treating the underlying condition.
Although Light's criteria continue to serve as the standard diagnostic tool, ongoing research seeks to refine diagnostic thresholds and explore adjunctive biochemical markers and imaging modalities to improve sensitivity and specificity in distinguishing effusion types and identifying underlying etiologies.
Several international studies have described the epidemiology and causes of pleural effusion across different populations; however, data from Egypt remain limited, particularly from tertiary care centers such as Mansoura University Hospitals. Understanding the patterns and etiologies of pleural effusion within a specific population-especially in regions with distinct epidemiological characteristics-is essential from both scientific and clinical perspectives.
Accurate categorization into transudative and exudative effusions using biochemical and imaging criteria allows clinicians to tailor the diagnostic approach appropriately. While transudative effusions often require conservative management targeting the primary systemic condition, exudative effusions frequently necessitate more invasive investigations, including pleural biopsy, thoracoscopy, or advanced imaging techniques to establish a definitive diagnosis.
Such stratification helps minimize unnecessary invasive procedures, reduce diagnostic delays, and optimize healthcare resource utilization-particularly in settings with limited access to advanced interventional diagnostics. Furthermore, local data regarding prevalence and clinical presentation provide valuable insights into regional disease burdens, such as higher rates of tuberculosis or malignancy, thereby supporting more effective healthcare planning and targeted management protocols.
Finally, adopting a comprehensive approach that integrates clinical assessment, radiological findings, and pleural fluid analysis aligns with contemporary evidence-based recommendations for pleural disease evaluation, ensuring that the study findings are applicable to both local and international clinical practice.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pleural effusion | – | Diagnostic Test: Pleural effusion pathologyevaluate the patterns, clinical features, pleural fluid characteristics, and etiologies of Pleural effusion among patients treated at Mansoura University, providing a comprehensive overview of the disease in this region. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients (>18 years) diagnosed with pleural effusion between January 2020 and December 2025.
Key inclusion criteria (2 listed)
- All patients with documented pleural effusion confirmed by chest imaging (X-ray, ultrasound, or CT).
- Patients with complete clinical, laboratory, and radiological records.
Key exclusion criteria (3 listed)
- Patients with incomplete medical records.
- Pediatric patients (<18 years).
- Patients with post-surgical pleural collections unrelated to systemic or pathological causes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pleural effusion pathologydescribe the demographic and clinical characteristics of patients presenting with pleural effusion. To classify pleural effusions into transudates and exudates using Light's criteria. To determine the most common etiologies of pleural effusion in Mansoura University. To evaluate the relationship between clinical presentation, radiological findings, | Diagnostic test | Pleural effusion |
Primary outcome
Distribution of underlying etiologies of pleural effusion among patients treated at Mansoura University Hospitals
Time frame: 5 years
Number of patients diagnosed with each underlying cause of pleural effusion (e.g., malignancy, tuberculosis, parapneumonic effusion, heart failure, liver cirrhosis, renal failure, and others) based on clinical evaluation, radiological findings, and pleural fluid analysis.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2026.
Related trials for Pleural Mesothelioma
RecruitingPhase 1/2
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma, Advanced
RecruitingPhase 2
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Pleural Mesothelioma, Pleural Diseases
Active, not recruitingPhase 1
Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma, Advanced
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 1
SW-682 in Advanced Solid Tumors
Advanced Solid Tumor, Mesothelioma, Malignant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohamed AbdElmoniem principal investigator
Lecturer of chest medicine faculty of medicine Mansoura university
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pleural Mesothelioma, run by Mansoura University Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distribution of underlying etiologies of pleural effusion among patients treated at Mansoura University Hospitals (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026.